The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRGβs approach to GIST research through real world evidence, relies on timely, accurate data from the patientβs perspective, with patient survival as the primary objective.
RECENT LRG DATA
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
Common Side Effects & How to Manage Them
Every GIST patient (and person in general) is unique, however, there are some common issues that patients may face during their GIST journey.
Tissue Testing Project
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
Flu Season 2021
Fall is finally here, and with it comes the onset of Flu Season. Flu is a difficult illness for everyone, but for cancer patients, it can be devastating. It is especially confusing in this year which continues to challenge everyone with the uncertainty of COVID-19 and its variants.
It’s Time to Rethink Placebos in Advanced GIST – LRG Science
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
New Research Lab Dedicated to GISTer
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
October 2nd GIST DO IT Walk NJ Postponed
The welfare of our members and staff is of utmost importance to us and due to ongoing pandemic, we have decided to take the precaution of postponing our GIST DO IT Walk which was scheduled for October 2nd.
Thank You to Our Newest GEM!
Our GEM Donor Program has a group of new donors that will help the LRG continue the work we do with patients and #GISTresearch. Our thanks go out to our newest GEM!
New Study Aids in the Diagnosis of Hereditary Paraganglioma and Pheochromocytoma
A recent study in Cancer Genetics, International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma, is important for GIST patients who carry a germline SDHB mutation




























